2 weeks Ago By ABMN Staff
Immunocore Holdings plc ( NASDAQ:IMCR – Free Report ) – Research analysts at HC Wainwright reduced their Q3 2024 earnings per share (EPS) estimates for Immunocore in a report released on Wednesday, August 28th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.
60) for the quarter, down from their prior estimate of ($0.30). HC Wainwright currently has a “Buy” rating and a $100.
00 price target on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($1.98) per share.
HC Wainwright also issued estimates for Immunocore’s Q4 2024 earnings at ($0.82) EPS, FY2024 earnings at ($2.14) EPS, Q1 2025 earnings at ($0.
44) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($1.
24) EPS, FY2025 earnings at ($2.99) EPS and FY2026 earnings at ($0.68) EPS.
A number of other equities research analysts also recently issued reports on the company. Mizuho lowered their price objective on Immunocore from $90.00 to $88.
00 and set a “buy” rating on the stock in a research report on Monday, May 13th. Needham & Company LLC reiterated a “buy” rating and issued a $81.00 price objective on shares of Immunocore in a research report on Friday, August 9th.
Oppenheimer reissued an “outperform” rating and issued a $89.00 target price (up previously from $87.00) on shares of Immunocore in a research note on Friday, August 9th.
JPMorgan Chase & Co. reduced their target price on Immunocore from $70.00 to $66.
00 and set an “overweight” rating on the stock in a research note on Wednesday, July 10th. Finally, Barclays reduced their target price on Immunocore from $92.00 to $66.
00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.
com, Immunocore presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.70. Immunocore Trading Up 3.
6 % Shares of IMCR stock opened at $35.88 on Friday. The company has a debt-to-equity ratio of 1.
22, a quick ratio of 5.94 and a current ratio of 5.96.
Immunocore has a 52-week low of $33.04 and a 52-week high of $76.98.
The company has a market capitalization of $1.79 billion, a PE ratio of -29.41 and a beta of 0.
75. The business’s fifty day moving average is $37.50 and its 200 day moving average is $50.
19. Immunocore ( NASDAQ:IMCR – Get Free Report ) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.
23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.25.
Immunocore had a negative return on equity of 16.54% and a negative net margin of 22.60%.
The company had revenue of $75.40 million for the quarter, compared to the consensus estimate of $74.58 million.
During the same quarter last year, the business posted ($0.37) earnings per share. The firm’s revenue was up 26.
2% compared to the same quarter last year. Institutional Trading of Immunocore A number of institutional investors have recently modified their holdings of IMCR. DNB Asset Management AS boosted its holdings in shares of Immunocore by 35.
0% during the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after purchasing an additional 1,868 shares during the period. NEOS Investment Management LLC purchased a new stake in shares of Immunocore during the fourth quarter worth about $262,000.
XTX Topco Ltd purchased a new stake in shares of Immunocore during the second quarter worth about $303,000. Tidal Investments LLC purchased a new stake in shares of Immunocore during the first quarter worth about $423,000. Finally, China Universal Asset Management Co.
Ltd. boosted its holdings in shares of Immunocore by 69.8% during the first quarter.
China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock worth $430,000 after purchasing an additional 2,721 shares during the period.
84.50% of the stock is currently owned by hedge funds and other institutional investors. About Immunocore ( Get Free Report ) Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. Featured Stories Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.
com's FREE daily email newsletter ..
